
ABSTRACT Objectives To evaluate the association between phosphorylated large tumor suppressor kinases 1 and 2 immunoreactivity and survival after radical cystectomy in patients with muscle‐invasive bladder cancer. Methods This retrospective study included 96 patients whose pretreatment transurethral resection specimens underwent phospho‐specific immunohistochemistry and digital H ‐score quantification. Associations with overall survival and metastasis or death after cystectomy were evaluated using multivariable Cox models. Continuous scores and median‐defined low/high groups were analyzed separately. Models incorporating lymphovascular invasion and surgical margin status included 95 patients. Nuclear Yes‐associated protein staining and paired transurethral resection–cystectomy specimens were additionally evaluated. Results During a median follow‐up of 67 months, 43 patients died and 47 experienced metastasis or death. Each 10‐point increase in H ‐score was associated with lower mortality (hazard ratio, 0.956; 95% confidence interval, 0.920–0.993; p = 0.020) and a lower risk of metastasis or death (hazard ratio, 0.962; 95% confidence interval, 0.929–0.996; p = 0.029). The adjusted low‐versus‐high mortality estimate was imprecise (hazard ratio, 1.777; 95% confidence interval, 0.871–3.624; p = 0.114). Nuclear Yes‐associated protein scores were higher in the low‐staining group ( p = 0.009). Among 71 paired specimens, H ‐scores were positively correlated (Spearman's ρ = 0.520), with 76.1% categorical agreement. Conclusions Lower phosphorylated large tumor suppressor kinases 1 and 2 H ‐scores were associated with shorter overall survival after radical cystectomy. These exploratory findings warrant independent validation, with residual confounding and uncertainty in binary‐group estimates limiting clinical interpretation.
ABSTRACT Objectives To characterize the frequency and clinical patterns of oligoprogression during systemic therapy for metastatic renal cell carcinoma (mRCC) and evaluate outcomes following metastasis‐directed therapy (MDT). Methods We retrospectively reviewed 261 patients with mRCC treated between 2007 and 2025. Oligoprogression was defined as progression in five or fewer lesions despite otherwise controlled disease. Cumulative incidence was estimated using competing‐risk analysis. Associations between MDT and treatment‐line outcomes were evaluated using time‐dependent Cox regression. Results Among 544 evaluable treatment‐line assessments from 261 patients, oligoprogression occurred in 63 (11.6%), representing 63 unique patients. Crude frequencies were 6.1%, 16.7%, and 16.5% during first‐, second‐, and third‐line therapy, respectively. The cumulative incidence was 8.8% at 6 months and 10.8% at 12 months. Fifty‐four patients (85.7%) had one or two progressing lesions. MDT was performed in 21 patients, whereas 42 received no MDT. Patients selected for MDT had a lower oligoprogressive lesion burden. In multivariable time‐dependent analysis, MDT was not associated with treatment‐line escalation alone (hazard ratio [HR], 1.05; 95% confidence interval [CI], 0.41–2.71), but was associated with a lower hazard of treatment‐line escalation or death (HR, 0.42; 95% CI, 0.19–0.94). The cumulative incidence of local progression after MDT was 26.7% at 12 months and 39.9% at 24 months. Conclusions Oligoprogression occurred in a clinically relevant subset of patients with mRCC. Although MDT was associated with favorable composite outcomes, substantial treatment selection limits causal interpretation.
ABSTRACT Objectives Treatment of localized renal cell carcinoma (RCC) in very elderly patients requires balancing oncological control against treatment‐related morbidity and competing mortality. We evaluated the clinical outcomes and safety of percutaneous cryoablation (PCA), focusing on patients aged ≥ 80 years. Methods We retrospectively analyzed 101 patients with localized RCC who underwent computed tomography–guided PCA between April 2014 and March 2022, including 61 aged < 80 years and 40 aged ≥ 80 years. Initial local control was assessed by routine renal biopsy 3 months after PCA. Overall survival (OS), cancer‐specific survival (CSS), conditional recurrence‐free survival (cRFS) after biopsy‐confirmed initial local control, renal function, and complications were evaluated. Results Median follow‐up was 52.7 months overall, 63.7 months in patients aged < 80 years, and 37.4 months in those aged ≥ 80 years. Three‐month biopsy was completed in 94 of 101 patients (93.1%), including 58 of 61 (95.1%) aged < 80 years and 36 of 40 (90.0%) aged ≥ 80 years. Among biopsy‐evaluable patients, 91 of 94 (96.8%) had no residual malignancy; in the ≥ 80‐year group, 34 of 36 (94.4%) had no residual malignancy. In patients aged ≥ 80 years, the 5‐year OS, CSS, and cRFS rates were 81.2% (95% CI, 68.4%–94.0%), 100%, and 81.8% (95% CI, 44.7%–95.1%), respectively. Grade ≥ 3 complications occurred in one patient aged ≥ 80 years (2.5%; cerebral infarction) and one aged < 80 years (1.6%; hematoma). Conclusions In this selected cohort of patients aged ≥ 80 years, PCA was associated with a high rate of biopsy‐confirmed initial local control and a low incidence of major complications.